The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has urged Indian pharmaceutical exporters to diversify shipping routes and explore alternative logistics options as tensions in the Gulf region threaten key global trade corrid...
AbbVie reported encouraging Phase 1 results for its experimental obesity therapy ABBV-295, showing meaningful weight loss and a favorable safety profile in adults during a 12–13 week clinical study.
Bristol Myers Squibb reported positive results from a late-stage trial of its experimental drug mezigdomide for multiple myeloma, showing improved progression-free survival in patients whose cancer returned or resisted prior treatment.
Neuland Laboratories is expanding into commercial peptide manufacturing with a new facility at its Bonthapally campus near Hyderabad. The first module, expected by summer 2026, already has USD 30 million in customer commitments.
Alcon launches Hydrus Microstent in India for minimally invasive glaucoma management. This device lowers intraocular pressure with proven clinical outcomes and rapid recovery.
AIIMS has signed an AIIMS-ISRO space medicine pact with the Indian Space Research Organisation to study how space affects the human body. The collaboration will support astronaut health research and strengthen India’s future human spaceflight mission
Lonza sells its Capsules & Health Ingredients unit for CHF 2.3B to Lone Star Funds, completing its shift to a pure-play CDMO. Proceeds will fuel growth, acquisitions, and share buybacks.
Lupin Ltd's Ankleshwar plant receives two observations from the U.S. FDA after inspection. The company promises to address the issues while adhering to CGMP standards for quality and safety.
Pfizer reported positive results for its experimental eczema drug tilrekimig after it met the main goal in a Phase 2 trial for moderate-to-severe atopic dermatitis. The company now plans to move the treatment into late-stage Phase 3 testing.
Sun Pharmaceutical has announced the acquisition of US oncology company Checkpoint Therapeutics for $355 million, including FDA-approved skin cancer drug UNLOXCYT, strengthening its global cancer treatment portfolio.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")